Myeloma cells act as tolerogenic antigen‐presenting cells and induce regulatory T cells in vitro

Regulatory T cells (Tregs) are essential for maintenance of self‐tolerance; however, tumor cells can exploit the tolerance to escape the immune system. We investigated the Tregs frequency in patients with multiple myeloma (MM) and in those with monoclonal gammopathy of undetermined significance (MGUS), and found that CD4+FoxP3+ and CD8+FoxP3+ Tregs were significantly increased in patients with MM and correlated with the active phase. Both Tregs subsets were expanded in cocultures of CD3+ lymphocytes and fresh CD138+ MM plasma cells or RPMI8226 and U266 cell lines and functioned as natural (n) and inducible (i) Tregs insofar as they inhibited the proliferation of stimulated CD3 lymphocytes via contact‐dependent and contact‐independent pathways. Induction of Tregs by MM plasma cells required a contact‐dependent pathway, implying antigen recognition by T cells. MM plasma cells acted as immature and tolerogenic antigen‐presenting cells (APCs), in that they displayed low CD80/CD86 expression associated with a phagocytic activity. By acting as immature APCs, MM plasma cells plausibly expand (n)Tregs and (i)Tregs both through conversion of CD3+FoxP3− into CD3+FoxP3+ T cells and proliferation of CD3+FoxP3+ T cells, which may suppress the anti‐MM immune response.

[1]  D. Atanackovic,et al.  FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells , 2014, Cancer Immunology, Immunotherapy.

[2]  S. Rutella,et al.  Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma , 2012, Journal of Translational Medicine.

[3]  M. Piskacek,et al.  Functionally Suppressive CD8 T Regulatory Cells Are Increased in Patients with Multiple Myeloma: A Cause for Immune Impairment , 2012, PloS one.

[4]  N. Nassif,et al.  CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis. , 2012, Blood.

[5]  C. Thompson,et al.  Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. , 2012, Blood.

[6]  G. Scott,et al.  Tumour Cell Generation of Inducible Regulatory T-Cells in Multiple Myeloma Is Contact-Dependent and Antigen-Presenting Cell-Independent , 2012, PloS one.

[7]  L. Walker,et al.  The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses , 2011, Nature Reviews Immunology.

[8]  L. Kumar,et al.  Significantly reduced regulatory T cell population in patients with untreated multiple myeloma. , 2011, Leukemia research.

[9]  H. Johnsen,et al.  Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA‐DR−/low Myeloid‐Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma , 2010, Scandinavian journal of immunology.

[10]  F. Dammacco,et al.  Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. , 2010, Blood.

[11]  P. Selby,et al.  CD4+CD25+FoxP3+ regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+ Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden , 2009, British journal of haematology.

[12]  D. Joshua,et al.  Regulatory T cells and multiple myeloma. , 2008, Clinical lymphoma & myeloma.

[13]  M. Andersson,et al.  Expansion of immunoglobulin autoreactive T-helper cells in multiple myeloma. , 2008, Blood.

[14]  C. Bokemeyer,et al.  CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation , 2008, Haematologica.

[15]  D. Munn,et al.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.

[16]  T. Curiel,et al.  Tregs and rethinking cancer immunotherapy. , 2007, The Journal of clinical investigation.

[17]  S. Ziegler,et al.  FOXP3 modifies the phenotypic and functional properties of regulatory T cells , 2007, Nature Reviews Immunology.

[18]  Helen Y Wang,et al.  Regulatory T cells and cancer. , 2007, Current opinion in immunology.

[19]  Ximing J. Yang,et al.  Tumor Evasion of the Immune System by Converting CD4+CD25− T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-β , 2007, The Journal of Immunology.

[20]  R. Lechler,et al.  Regulatory T cells and transplantation tolerance. , 2006, Human immunology.

[21]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[22]  T. Giese,et al.  In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. , 2006, Blood.

[23]  L. Cosmi,et al.  Thymic regulatory T cells. , 2005, Autoimmunity reviews.

[24]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[25]  M. Dhodapkar,et al.  Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy , 2003, The Journal of experimental medicine.

[26]  L. Cosmi,et al.  Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. , 2003, Blood.

[27]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[28]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[29]  D. Joshua,et al.  T cells in myeloma , 2003, Hematological oncology.

[30]  M. Baccarani,et al.  Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. , 2002, Blood.

[31]  F. Dammacco,et al.  Deregulated cytokine network and defective Th1 immune response in multiple myeloma , 2001, Clinical and experimental immunology.

[32]  T. Mak,et al.  Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.

[33]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[34]  A. Osterborg,et al.  Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells. , 1997, Blood.

[35]  L. Pilarski,et al.  In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. , 1995, Blood.

[36]  L. Pilarski,et al.  In Multiple Myeloma, Clonotypic B Lymphocytes Are Detectable Among CD19+ Peripheral Blood Cells Expressing CD38, CD56, and Monotypic Ig Light Chain , 1995 .

[37]  A. Lefvert,et al.  Anti‐idiotypic antibodies in patients with monoclonal gammopathies: relation to the tumour load , 1991, British journal of haematology.

[38]  A. Rudensky,et al.  Immunoglobulin‐specific T‐B cell interaction , 1989, European journal of immunology.

[39]  H. Eisen,et al.  Myeloma proteins as tumor-specific transplantation antigens. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Roberto A. Maldonado,et al.  How tolerogenic dendritic cells induce regulatory T cells. , 2010, Advances in immunology.

[41]  N. Munshi,et al.  Dysfunctional T regulatory cells in multiple myeloma. , 2006, Blood.